Ipsen recovers an epizyme focused on blood cancer – Find out why

Ipsen S.A. IPSEY agreed to acquire Epizyme Inc. EPZM at $1.45 per share for approximately $247 million, plus a contingent value right (CVR) per share.

  • The deal is expected to close by the third quarter.
  • The primary focus of the acquisition is Epizyme’s lead drug, Tazverik (tazemetostat), a chemotherapy-free EZH2 inhibitor, which received accelerated FDA approval in 2020.
  • It is currently indicated in adult patients with relapsed or refractory follicular lymphoma (FL) with EZH2 mutations who have not responded to other treatments.
  • It is also indicated for patients 16 years of age and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
  • Tazverik is currently in a Phase 3 trial in combination with rituximab and lenalidomide (R2) in patients with relapsed/refractory FL who have received at least one prior therapy.
  • The initial reading of the data is scheduled for 2026.
  • Each CVR is eligible for deferred cash payments of $0.30 payable upon first achieving $250 million in Tazverik sales in any four consecutive quarters through 2026.
  • An additional $0.70 per CVR is payable upon FDA approval for Tazverik and R2 combo in second-line follicular lymphoma by January 1, 2028.
  • Ipsen will also acquire Epizyme’s oral SETD2 inhibitor candidate, EZM0414, currently in Phase 1/1b for relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma, as well as preclinical programs focused on epigenetic targets.
  • The acquisition of Epizyme will immediately provide incremental sales and leverage the US business infrastructure.
  • Ipsen expects the transaction to be moderately dilutive on its current operating income until the end of 2024.
  • Price Action: EPZM shares rose 59.33% to $1.52 in the premarket session of the last check on Monday.

About Michelle Anderson

Check Also

CTA chairman skips city council hearing focused on transit agency service and safety issues | Chicago News

This file photo shows a southbound CTA Red Line train in Chicago. (WTTW News) Called …